Description
Recombinant Human TIGIT Protein (aa 1-138, His Tag)(Active) | PKSH031356 | Gentaur US, UK & Europe Disrtribition
Synonyms: T-cell immunoreceptor with Ig and ITIM domains;;VSIG9; VSTM3;TIGIT;V-set and transmembrane domain-containing protein 3;V-set and immunoglobulin domain-containing protein 9
Active Protein: Active protein
Activity: A DNA sequence encoding the extracellular domain of human TIGIT (NP_776160.2) (Met 1-Phe 138) with a C-terminal polyhistidine tag was expressed.
Protein Construction: A DNA sequence encoding the extracellular domain of human TIGIT (NP_776160.2) (Met 1-Phe 138) with a C-terminal polyhistidine tag was expressed.
Fusion Tag: C-His
Species: Human
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 85 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg of the protein as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 14.2 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: TIGIT; also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain; a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory; memory; activated T cells and NK cells. It binds PVR with high affinity; and PVRL2 with lower affinity; but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses; however; TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition; TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Immune CheckpointImmune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: immunology
